文献速递中枢神经肿瘤放疗胸部肿瘤放疗

非小细胞肺癌脑转移大分割立体定向放疗的预后因素、失败模式与再照射

Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-08-24

该研究纳入2018年5月至2022年5月接受大分割立体定向放疗(fSRT)的218例非小细胞肺癌脑转移患者,中位随访22.3个月,分析颅内局部复发、颅内进展及症状性放射性坏死的累积发生率,并探讨再照射(re-fSRT)的临床价值。结果显示fSRT是局限性脑转移的有效治疗,部分患者可从re-fSRT中获益。

要点

  • 1年、2年、3年颅内局部复发累积发生率分别为8.1%、12.3%、17.8%。
  • 59例颅内进展患者中45例(76.3%)适合re-fSRT,其中19例(42.2%)实际接受并与生存改善相关(p=0.010)。
  • 全人群1年、2年、3年症状性放射性坏死累积发生率分别为4.5%、10.3%、17.7%,Brain V20Gy与sRN风险相关。

核心结论

  • fSRT是局限性非小细胞肺癌脑转移的有前景的治疗方式,部分患者可从re-fSRT中获益。

研究设计与样本

  • 研究纳入2018年5月至2022年5月连续接受fSRT治疗脑转移的非小细胞肺癌患者218例,中位随访22.3个月。
  • 以死亡为竞争事件计算颅内局部复发、颅内进展和症状性放射性坏死的累积发生率。
  • 将12个月内发生颅内进展但数量≤5个且大小≤3 cm、无颅内局部复发的患者定义为re-fSRT候选者。

主要发现

  • 218例患者1年、2年、3年颅内局部复发累积发生率分别为8.1%、12.3%、17.8%。
  • 生物有效剂量、总肿瘤体积和同期全身治疗与颅内局部复发风险相关。
  • 59例颅内进展患者中45例(76.3%)适合re-fSRT,其中19例(42.2%)实际接受re-fSRT并与生存改善相关(p=0.010)。
  • 全人群1年、2年、3年症状性放射性坏死累积发生率分别为4.5%、10.3%、17.7%。
  • 接受re-fSRT的患者中3例(15.8%)发生症状性放射性坏死,Brain V20Gy与症状性放射性坏死风险相关。

关键数值与推荐

  • re-fSRT候选标准:12个月内发生颅内进展,进展病灶数量≤5个且大小≤3 cm,且无颅内局部复发。

临床怎么用

  • 对局限性非小细胞肺癌脑转移患者可考虑fSRT治疗。
  • 对符合候选标准的颅内进展患者可评估re-fSRT,其与生存改善相关。
  • 关注Brain V20Gy以评估症状性放射性坏死风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce. METHODS: Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included. The cumulative incidence of intracranial local recurrence (iLR), intracranial progressive disease (iPD) and symptomatic radiation necrosis (sRN) were calculated from the initiation of fSRT, choosing death as the competing event. Patients with limited iPD (number ≤5 and size ≤3 cm) and without iLR developed within 12 months, were classified as re-fSRT candidates. The clinical value of re-fSRT and dosimetric predictors of sRN were investigated. RESULTS: With a median follow-up of 22.3 months, the 1-year, 2-year and 3-year cumulative incidence of iLR among the 218 identified patients were 8.1 %, 12.3 %, 17.8 %, respectively. Biological effective dose, total tumor volume and concurrent systemic therapy were associated with the risk of iLR. Notably, 45 (76.3 %) of the 59 patients with iPD were feasible for re-fSRT. Re-fSRT was performed in 19 (42.2 %) of the 45 candidates and associated with improved survival (p = 0.010). The 1-year, 2-year and 3-year cumulative incidence of sRN in the whole population were 4.5 %, 10.3 %, 17.7 %, respectively. Moreover, sRN occurred in 3 (15.8 %) patients receiving re-fSRT and Brain V20Gy was found to be associated with the risk of sRN. CONCLUSION: fSRT is a promising treatment for limited BMs from NSCLC and some patients may benefit from re-fSRT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu D, Pang Y, Qu J, et al. Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer. Clin Transl Radiat Oncol. 2025. PMID: 40919115. doi:10.1016/j.ctro.2025.101038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。